The Complete 2026 Guide to US FDA Food & Supplement Compliance

Selling foods or dietary supplements in the US in 2026 means getting three things right: classification, labeling, and claims substantiation; and building a workflow that keeps packaging, web copy, and ads aligned. This guide explains what the FDA regulates (and where the FTC fits), the labeling pillars teams most often miss, how to think about Nutrition Facts vs Supplement Facts, and practical checklists to reduce warning-letter and recall risk. It’s general information, not legal advice.

Food vs dietary supplements: what changes from a compliance standpoint (US FDA food and dietary supplement compliance 2026)

A product’s regulatory category drives the rules you’ll live under: which facts panel you use, what claims are allowed, and which cGMP requirements apply.

At a high level:

• Foods use Nutrition Facts (21 CFR 101.9) and are subject to food cGMPs and preventive controls (21 CFR Part 117). (Code of Federal Regulations)

• Dietary supplements use Supplement Facts (21 CFR 101.36) and are subject to dietary supplement cGMPs (21 CFR Part 111). (Code of Federal Regulations; FDA)

FDA also emphasizes a common misconception: dietary supplements are not “FDA approved” for safety and effectiveness before sale. (FDA)

Quick rule of thumb

Use these as early screening questions (not a substitute for a formal classification review):

• If it’s consumed as a conventional food or beverage (meals, snacks, most drinks) → Food (Nutrition Facts).

• If it’s intended to supplement the diet and contains dietary ingredients (vitamins, minerals, herbs/botanicals, amino acids, etc.) and is labeled as such → Dietary supplement (Supplement Facts).

• If your marketing implies it treats, cures, prevents, or mitigates disease → you may be drifting into drug territory (high enforcement risk), regardless of what the label calls it. (FDA)

Table: Food vs supplement compliance differences

Alt text: Table comparing FDA compliance requirements for foods vs dietary supplements (facts panel, claims, cGMP, and common risk areas).

What FDA regulates, and where FTC fits in

Most teams get into trouble because they review the label but forget the label is only part of the marketing surface area.

FDA (labeling + product safety baseline)

FDA’s core focus is whether products are:

• Misbranded (e.g., labeling required elements missing or misleading)

• Adulterated (e.g., unsafe ingredients/contamination; supplements containing undeclared drugs)

• Manufactured under applicable cGMP expectations (foods: Part 117; supplements: Part 111) (FDA; Code of Federal Regulations)

FTC (advertising substantiation)

The FTC oversees whether advertising is truthful, not misleading, and substantiated—especially online claims, influencer content, testimonials, and paid ads. FTC’s Health Products Compliance Guidance (Dec 2022) is the current anchor resource on substantiation expectations for health-related product claims. (FTC)

Practical takeaway: your review process should cover PDP + info panel + inserts + Amazon bullets + website PDPs + paid social + email + influencer scripts as one claims system.

Core FDA labeling requirements (foods)

Food labels have several “always-needed” building blocks. Errors here are frequent because they’re operational: you’re managing packaging artwork, co-manufacturer specs, and frequent edits.

Principal display panel (PDP) basics

The PDP is the part of the label most likely to be displayed under customary retail conditions. (21 CFR 101.1)

Typically, the PDP must include:

• Statement of identity (what the food is) (21 CFR 101.3)

• Net quantity of contents (how much is in the package) (FDA; CFR frameworks)

Even when the copy is directionally right, brands often slip on:

• Inconsistent product naming between PDP and information panel

• Net quantity placement/legibility after resizing packaging

• “Cute” marketing names that obscure the food’s identity (e.g., brand name only, no clear identity)

Information panel essentials

The information panel is generally the label panel immediately to the right of the PDP (with packaging exceptions). (21 CFR 101.2)

Common required components include:

• Ingredient statement (21 CFR 101.4)

• Name and place of business (manufacturer/packer/distributor)

• Nutrition Facts (unless exempt) (21 CFR 101.9)

Key ingredient list rule: ingredients generally must be listed by common or usual name in descending order of predominance by weight. (21 CFR 101.4)

Allergen labeling (what teams miss most often)

Allergen issues are among the most expensive “small mistakes,” because fixes often require reprints, relabeling, or recalls.

In the US, FDA recognizes nine major food allergens (“Big 9”): milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. Sesame became the ninth major allergen with required labeling effective January 1, 2023. (FDA)

FDA explains that major allergens must be declared clearly—commonly either:

• in parentheses after the ingredient (e.g., “whey (milk)”), or

• in a Contains statement adjacent to the ingredient list. (FDA)

Also:

• tree nuts must specify the nut type

• fish and crustacean shellfish must specify the species (FDA)

Allergen checklist (fast pass)

• Do any ingredients, flavors, colors, or processing aids contain a Big 9 allergen?

• If yes, does the allergen food source appear clearly via:

  • parentheses in the ingredient list and/or

  • a “Contains” statement (FDA)?

• If using fish/tree nuts/shellfish, did you specify species/type (FDA)?

• Did recent reformulations introduce sesame (e.g., tahini, sesame flour, sesame oil), and did the label keep up (FDA)?

• Did you re-check allergens after changing suppliers (common hidden risk)?

Nutrition Facts vs Supplement Facts (what’s different)

These panels look similar to consumers, but the underlying requirements and “gotchas” are different.

When you use Nutrition Facts

Nutrition Facts is used for conventional foods and most beverages and is governed by 21 CFR 101.9. (Code of Federal Regulations)

Common operational errors include:

• serving size logic not matching the package presentation (especially multi-serving resealable packages)

• inconsistent nutrient values between spec sheets and final artwork after reformulation

• forgetting to re-check claims after a Nutrition Facts update (e.g., “good source of…” claims tied to nutrient levels)

When you use Supplement Facts

Supplement Facts is used for dietary supplements and is governed by 21 CFR 101.36. (Code of Federal Regulations)

Common mistakes in supplement panels often include:

• confusing dietary ingredients vs other ingredients

• inconsistent units/forms (e.g., mg vs mcg) across SKUs

• listing botanicals without adequate specificity (FDA warning letters sometimes cite missing plant part for botanicals) (FDA warning letter examples; 21 CFR 101.4 concepts)

Practical pre-print checklist (run before ordering packaging)

Use this before you approve a print run or upload final artwork to a retailer portal.

Label mechanics

• PDP clearly shows statement of identity and net quantity (21 CFR 101.1; 21 CFR 101.3).

• Information panel elements are present and readable (21 CFR 101.2).

• Ingredient list is in descending order by weight and uses common/usual names (21 CFR 101.4).

Facts panel

• Correct panel type: Nutrition Facts (food) vs Supplement Facts (supplement) (21 CFR 101.9; 21 CFR 101.36).

• Values match your latest approved formulation/specs (internal spec control).

Allergens

• Big 9 allergens properly declared, including sesame (FDA).

• Fish/tree nut/shellfish species/type stated where required (FDA).

Claims

• Every on-pack claim appears in your claims inventory (see workflow section below).

• Claims align with your website and ads (FTC substantiation risk).

• Supplements with structure/function claims include DSHEA disclaimer and meet notification expectations (FDA).

Claims compliance in 2026: the categories and the red lines

FDA groups label claims into three broad buckets: nutrient content claims, health claims, and structure/function claims. (FDA)

A useful way to manage claims is to classify each claim, then apply the right approval and substantiation path.

Nutrient content claims (foods and sometimes supplements)

These characterize the level of a nutrient (e.g., “high,” “good source,” “low”). Nutrient content claims generally must meet specific regulatory definitions/conditions. (FDA)

Operational tip: if you change formulation, supplier, serving size, or panel calculations, re-check every nutrient content claim—because eligibility can change.

Health claims (higher scrutiny)

Health claims describe a relationship between a substance and a disease or health-related condition and generally require FDA authorization or must fit within FDA’s permitted frameworks. (FDA)

If you’re not sure whether you’re making a health claim, treat it as a “stop and review” moment—these often drive both FDA and competitor scrutiny.

Structure/function claims (dietary supplements)

Structure/function claims describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the body (e.g., “supports bone health”). (FDA)

For dietary supplements, FDA states key conditions for 403(r)(6) structure/function claims, including:

• the claim must be truthful and not misleading

• it must be substantiated

• it must be accompanied by the DSHEA disclaimer

• the claim must not be a disease claim

• the firm must notify FDA within 30 days after first marketing the product with the claim (FDA)

2026 nuance worth noting: FDA’s Dec 11, 2025 industry letter reiterates expectations around disclaimer placement/linking for structure/function claims and announces enforcement discretion on a narrow “each panel” issue, while still expecting inclusion and clear linkage to each applicable claim. (FDA)

Disease claims: the fastest path to enforcement

Disease claims explicitly or implicitly claim to diagnose, mitigate, treat, cure, or prevent disease. FDA enforcement actions frequently focus on disease claims—particularly when products are sold as supplements but marketed like drugs. (FDA)

Examples of high-risk disease claims:

• “Treats diabetes.”

• “Prevents Alzheimer’s.” (FDA has issued warning/advisory letters targeting Alzheimer’s treatment/prevention claims.) (FDA)

• “Cures arthritis.”

Safer (but still substantiation-required) alternatives that generally stay in structure/function territory:

• “Helps maintain healthy blood sugar already within the normal range.”

• “Supports brain health and cognitive function.”

• “Supports joint mobility.”

Testimonial trap: if a customer review or influencer post says, “This cured my migraines,” and you repost it in marketing, you may be adopting a disease claim. FTC and FDA risk often increases when brands amplify unverified disease outcomes.

Table: claim types and relative risk

Alt text: Table summarizing FDA claim categories, examples, and relative enforcement risk.

Ingredient and safety basics (foods and supplements)

Foods: GRAS and food additive concepts (high level)

FDA explains that substances intentionally added to food are generally food additives that require premarket review/approval unless the substance is GRAS (generally recognized as safe) for its intended use or otherwise excluded. FDA also describes a voluntary GRAS notification program and the types of responses FDA issues. (FDA)

Practical operator takeaway: “GRAS” is not a marketing phrase; it’s a safety/regulatory status question tied to use levels, food category, and exposure. If you’re using a novel ingredient or novel use level, this is a review gate.

Supplements: New Dietary Ingredient (NDI) considerations (high level)

Under US law, a “new dietary ingredient” (NDI) is a dietary ingredient not marketed in the US in a dietary supplement before October 15, 1994, and it can trigger premarket notification requirements. (21 U.S.C. 350b)

FDA has continued to update educational materials and guidance around the NDI notification process (including 2024 guidance activity and 2025 educational materials). (FDA)

Practical triggers for an NDI review often include:

• a new botanical not previously marketed in supplements

• a new form/extract/process that changes the ingredient’s identity/exposure

• a new route of use or high exposure scenario

“Adulteration” and “misbranding” in plain English

• Misbranding often means the label is missing required information or is misleading (e.g., missing allergen disclosure; missing required supplement identity elements; improper claims framing).

• Adulteration often means there’s a safety issue (e.g., contamination; unsafe ingredient; undeclared drug ingredients in “supplements”).

A particularly important supplement risk: FDA has an import alert covering products marketed as foods/supplements that contain undeclared active pharmaceutical ingredients—commonly in sexual enhancement, weight loss, and muscle-building categories. (FDA Import Alert 54-16)

Manufacturing expectations: cGMP and quality systems

Dietary supplement cGMP (21 CFR Part 111)

Dietary supplement manufacturers must follow cGMP requirements in 21 CFR Part 111. (Code of Federal Regulations)

At an operational level, teams should expect to have documented controls around:

• identity and composition specifications

• supplier qualification and incoming material controls

• testing/verification consistent with the firm’s quality system

• batch records and complaint handling

Food safety systems (FSMA context, high level)

Food manufacturing is governed by food cGMPs and, for many facilities, hazard analysis and risk-based preventive controls under 21 CFR Part 117. (FDA)

2026 note (planning horizon): FDA’s Food Traceability Rule (FSMA 204) originally had a Jan 20, 2026 compliance date, but FDA states Congress directed FDA not to enforcethe rule prior to July 20, 2028. (FDA) Many brands are using 2026–2027 to map traceability data across suppliers so implementation isn’t a last-minute scramble.

What enforcement looks like: warning letters, recalls, and import risk

Understanding enforcement patterns helps teams prioritize what to fix before launch.

Common triggers include:

• Disease claims (especially supplements marketed to treat serious conditions) (FDA)

• Missing or incorrect allergen labeling (including sesame) (FDA)

• Misbranding of supplements (e.g., missing “dietary supplement” statement of identity or other required elements) (FDA warning letter patterns)

• Missing DSHEA disclaimer for supplement structure/function claims, or misuse of the disclaimer on conventional foods (FDA; FDA warning letter example)

• Tainted supplements with undeclared drug ingredients (FDA Import Alert 54-16)

A practical way to use FDA enforcement information:

• Periodically review FDA warning letters in your category (e.g., “dietary supplement” + “misbranded”).

• Extract the “why FDA cared” pattern, then turn it into internal checklist items.

A practical compliance workflow for teams shipping in the US

The fastest way to reduce compliance surprises is to treat compliance like a product system, not a last-minute label proof.

Who should be in the loop

• Regulatory Affairs (owner of interpretation and final sign-off)

• Quality / Food Safety (specs, suppliers, cGMP expectations)

• Legal / Compliance (risk review, claim substantiation posture)

• Marketing (copy, testimonials, influencer scripts, ads)

• Ops / Supply Chain (supplier changes, packaging change control)

Stage-gate workflow (repeatable)

1. Classify the product (food vs supplement; confirm panel type) (21 CFR 101.9; 21 CFR 101.36).

2. Confirm ingredient status and specs

   • foods: GRAS/food additive posture where relevant (FDA)

   • supplements: NDI questions when applicable (21 U.S.C. 350b; FDA)

3. Draft label + build a claims inventory

   • list every on-pack and off-pack claim and where it appears (PDP, website, Amazon, ad)

4. Substantiation check (label + ads)

   • FTC expects substantiation before dissemination for health-related claims (FTC)

5. Final label proof check

   • PDP + info panel placement, ingredient order, allergen declarations, facts panel accuracy (FDA; 21 CFR 101.1–101.4)

6. Change control + recordkeeping

   • keep a record of what was approved, by whom, when, and why (especially for claims and disclaimers)

“Definition of done” (launch readiness)

• Final artwork matches approved formulation and spec version.

• All Big 9 allergens are declared correctly, including sesame (FDA).

• Claims are categorized (nutrient content vs health vs structure/function) and substantiated (FDA; FTC).

• Supplements with 403(r)(6) structure/function claims include DSHEA disclaimer and meet FDA notification expectations (FDA).

• Label, website, and ads are aligned, no “extra” disease claims living only online.

Where Taama fits (factual)

Taama is a CPG regulatory compliance and market expansion platform used by food, beverage, and supplement teams to run regulatory checks against core product inputs such as ingredient lists, formulations, label content, and supporting compliance documentation. The platform is designed to identify potential compliance risks, including missing allergen disclosures, non-compliant claims, expired certifications, or absent mandatory label elements, before products move into packaging, commercialization, or market launch stages.

In addition to reviewing artwork and label content, Taama processes supporting compliance documents such as laboratory test reports, certificates, supplier documentation, and product certifications. These materials are evaluated for completeness and validity, tracked over time, and connected to the specific ingredients, products, and claims they support, helping teams ensure that marketing and regulatory decisions remain backed by current evidence.

In practice, teams use platforms like Taama to introduce greater structure and consistency into compliance workflows that are often fragmented across functions and systems. Common use cases include:

• Creating repeatable cross-functional review workflows spanning Regulatory Affairs, Quality, Packaging, and Marketing teams

• Maintaining a centralized, audit-ready record of label versions, compliance decisions, and supporting documentation

• Verifying that required evidence is complete and still valid, including lab tests, certifications, and supplier documents tied to product claims

• Catching issues earlier in the product lifecycle, reducing costly last-minute artwork changes, launch delays, or retailer escalations

• Supporting multi-market expansion planning by evaluating whether products meet regulatory expectations before entering new regions

Rather than replacing artwork or supplier systems, platforms in this category typically act as a decision layer; helping teams interpret regulatory requirements, connect evidence to claims, and translate compliance requirements into actionable product and labeling decisions.

You can learn more about Taama’s approach on its website and company overview pages.

Conclusion: 5 takeaways and next steps

1. Classification comes first. Food vs supplement determines the facts panel, claim pathways, and cGMP expectations. (FDA; CFR)

2. Label basics are non-negotiable. PDP/info panel placement, ingredient list logic, and allergen labeling (including sesame) are frequent failure points. (FDA; 21 CFR 101.1–101.4)

3. Claims are a system across label + web + ads. FDA and FTC risks often come from inconsistency and overreach. (FDA; FTC)

4. Supplements must avoid disease claims and follow DSHEA conditions.Structure/function claims require substantiation, disclaimers, and FDA notification timing. (FDA)

5. Build a workflow, not a scramble. A repeatable stage-gate review reduces costly reprints and faster corrective actions when rules or marketing changes.

Do this next (practical actions)

• Run a claims inventory across packaging, PDPs, retailer listings, ads, and influencer content.

• Align label + website + ads so you don’t unintentionally create a disease claim online.

• Document substantiation and approvals (FTC-ready recordkeeping mindset).

• Implement a stage-gated review and change control process before each print run.

• Schedule periodic audits (including allergen and claim re-checks after supplier or formula changes).